Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

Rhea-AI Summary

Iridex (Nasdaq: IRIX) announced publication of an independent retrospective study in Ophthalmology and Therapy showing that retreatment with MicroPulse TLT safely and effectively lowers intraocular pressure (IOP) in glaucoma patients.

The study of 76 eyes at University Eye Clinic Maastricht found meaningful IOP reductions ~25%–35% at three months after retreatment across patient groups. Retreatment timing varied from about 4 months to > 28 months, with second-retreatment intervals of ~3 months to 2 years, supporting repeatability and flexible use in real-world practice.

Positive

• IOP reduction of approximately 25%–35% at 3 months
• Study included 76 eyes from real-world clinical practice
• Retreatment timing flexibility: 4 months to >28 months
• Second-retreatment intervals documented: ~3 months to 2 years

Negative

• Study is retrospective and nonrandomized, limiting causal inference
• No long-term (>3 months) aggregated durability data presented

Key Figures

Sample size 76 eyes Retrospective MicroPulse TLT retreatment study in glaucoma

Follow-up period 3 months Post-retreatment intraocular pressure assessment

IOP reduction range 25% to 35% Intraocular pressure reduction three months after retreatment

Early retreatment timing 4 months Average first retreatment timing for nonresponders

Late retreatment timing more than 28 months Average first retreatment timing for late-attrition patients

Second retreatment interval (short) 3 months Shortest interval between first and second retreatments

Second retreatment interval (long) nearly 2 years Longest interval between first and second retreatments

Market Reality Check

$0.9208 Last Close

Volume Volume 107,334 is at 1.05x its 20-day average of 101,975 shares. normal

Technical Price $0.939 is trading below the 200-day MA of $1.10 and 50% under the 52-week high.

Peers on Argus

Peers showed mixed moves: TRIB -5%, PTHL -6.28%, ADGM +5.59%, VVOS +2.82%, NSYS +0.2%. With IRIX up 2.48%, the pattern suggests a stock-specific reaction rather than a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Clinical modeling study	Positive	-1.7%	Thermal dynamics modeling showed MicroPulse TLT with lower peak temperatures.
Dec 05	Investor conference	Positive	+1.3%	Announcement of Sidoti virtual conference presentation and investor access.
Nov 11	Earnings release	Positive	+8.2%	Q3 2025 revenue growth with improved adjusted EBITDA loss and guidance.
Oct 28	Earnings preview	Neutral	+2.0%	Scheduled Q3 2025 results release and conference call details.
Sep 09	Listing compliance	Positive	-2.8%	Nasdaq confirmed regained compliance with continued listing requirements.

Pattern Detected

Recent fundamentally positive events, including Q3 earnings and compliance resolution, have produced mixed price reactions, with both alignments and divergences relative to news tone.

Recent Company History

Over the last six months, IRIDEX has reported several operational and clinical milestones. Q3 2025 results showed revenue growth and improved losses, while a later 10-Q detailed higher cash and increased stockholders’ equity. The company regained Nasdaq listing compliance on Aug 27, 2025. Multiple investor events and new MicroPulse-related studies, including thermal dynamics modeling and today’s retreatment study, reinforce a focus on glaucoma technologies. Price reactions to these updates have alternated between positive alignment and brief pullbacks.

Market Pulse Summary

This announcement added independent, real-world evidence for MicroPulse TLT in glaucoma, demonstrating retreatment can yield additional 25–35% intraocular pressure reductions across 76 eyes. It complements earlier thermal dynamics work and recent Q3 2025 results, where Cyclo G6 and retina systems supported revenue growth. Investors may watch for further clinical publications, adoption trends, and subsequent earnings to gauge how these data translate into procedure volumes and system demand.

Key Terms

transscleral laser treatment medical

"retreatment of transscleral laser treatment using MicroPulse® technology"

Transscleral laser treatment is a medical procedure that uses a focused laser beam delivered through the white outer layer of the eye to treat conditions such as glaucoma or tumors without cutting through the surface. Think of it as using a spotlight shone through the wall to fix a problem inside; it can reduce symptoms, limit the need for ongoing medication, or enable less invasive care. For investors, the technique matters because its adoption affects demand for laser equipment, related consumables, clinical outcomes, reimbursement rates, and the competitive position of medical-device and ophthalmology service providers.

MicroPulse TLT medical

"retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT)"

Micropulse TLT (micropulse transscleral laser therapy) is a medical laser treatment for glaucoma that delivers short, repeated bursts of energy through the white of the eye to lower intraocular pressure while aiming to reduce tissue damage compared with continuous laser methods. For investors, it matters because adoption, regulatory approval, and insurance coverage drive device sales, recurring procedure volumes, and competitive positioning in ophthalmic markets—similar to how a gentler, more efficient tool can replace an older, harsher one in a trade.

intraocular pressure (IOP) medical

"further reduce intraocular pressure (IOP) in patients with glaucoma"

Intraocular pressure (IOP) is the fluid pressure inside the eye, like the air pressure inside a tire that keeps the eye’s shape and function stable. IOP matters to investors because persistently high pressure is the main risk factor for glaucoma and other vision problems, so IOP readings drive demand for medicines, devices and clinical trials, influence regulatory decisions, and can materially affect a healthcare company’s revenue outlook.

retrospective study medical

"a recently published independent, retrospective study in Ophthalmology and Therapy"

A retrospective study is a type of research that looks back at existing records, medical charts, or databases to identify patterns and outcomes that already happened. For investors, these studies can provide faster, lower‑cost evidence about a treatment’s safety or effectiveness—like reading past customer reviews—but they are more prone to missing information and bias than studies that collect data going forward, so their findings are suggestive rather than definitive.

non-incisional medical

"offers a valuable non-incisional option that can be tailored and repeated"

Non-incisional describes a medical procedure or technique that achieves a therapeutic result without making surgical cuts into the skin or tissues, often using injections, lasers, or device-based approaches. For investors, this matters because non-incisional options can mean lower procedure costs, faster patient recovery, fewer complications and shorter regulatory paths, which can increase market adoption, pricing pressure and predictable revenue compared with traditional surgery.

AI-generated analysis. Not financial advice.

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse^® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.¹

The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The study included 76 eyes from patients with moderate to advanced glaucoma who underwent retreatment following variable responses to their primary procedure. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment.

“These findings support retreatment with MicroPulse TLT as a valuable option in glaucoma care, particularly for patients who experienced an initial IOP-lowering benefit that diminished over time,” said lead author Dr. Ronald de Crom. “The results also indicate that long-term success and repeatability is most favorable in patients who responded to the primary treatment, helping clinicians better identify candidates for retreatment.”

Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition, depending on when the effect of the primary procedure began to diminish. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases. This variability demonstrates the procedure’s real-world flexibility in sustaining IOP control over time.

“We are encouraged by these new clinical data, which continue to validate MicroPulse TLT as a versatile and repeatable therapy for lowering IOP in patients across multiple stages of glaucoma,” said Patrick Mercer, President and CEO of Iridex. “This study reinforces what we hear from physicians globally, that MicroPulse TLT offers a valuable non-incisional option that can be tailored and repeated over time while maintaining a favorable safety profile. We remain committed to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.”

About Iridex Corporation 
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com

Media Contact
Joan Stauffer
jstauffer@iridex.com

For more information about Iridex technologies, visit www.iridex.com.

Iridex, the Iridex logo, MicroPulse^®, the MicroPulse logo, Cyclo G6, MicroPulse P3^®, and G-Probe^® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.

References

1. de Crom RMPC, Kujovic-Aleksov S, Webers Carroll AB, Berendschot Tos TJM, Beckers HJM. Efficacy, repeatability, and safety of retreatment with micropulse cyclophotocoagulation in the management of glaucoma. Ophthalmology and Therapy. 2025.

FAQ

What did Iridex announce about MicroPulse TLT on December 11, 2025 (IRIX)?

Iridex announced publication of an independent retrospective study showing retreatment with MicroPulse TLT lowered IOP by ~25%–35% at three months.

How many eyes and where was the MicroPulse TLT retreatment study published for IRIX?

The study included 76 eyes and was conducted at the University Eye Clinic Maastricht, published in Ophthalmology and Therapy.

What retreatment timing did the IRIX MicroPulse TLT study report?

Retreatment timing varied widely: averages ranged from about 4 months to more than 28 months, with some second-retreatment intervals of ~3 months to 2 years.

Does the IRIX study report MicroPulse TLT is safe for repeat treatments?

Yes; the independent study reported that retreatment was safe and repeatable, maintaining a favorable safety profile in the observed cohort.

Which patients showed the most favorable long-term repeatability in the IRIX study?

Patients who responded to the primary MicroPulse TLT procedure showed the most favorable long-term success and repeatability.